Skip to content
ClinCalc Pro
Menu
Gastroenterology Emergency Medicine Strong — internationally used grading system; endorsed by AASLD and EASL

West Haven Criteria for Hepatic Encephalopathy

Grades hepatic encephalopathy severity using the West Haven criteria (Grades 0–4), guiding management intensity in patients with liver disease.

Used in: Liver Disease & Cirrhosis

Score interpretation

Grade 0 — Covert HE / Minimal HE 0

No clinically detectable HE. Psychometric testing may show subtle impairment.

→ Identify and treat precipitants (infection, constipation, GI bleed, dehydration, sedatives). Lactulose for prophylaxis in recurrent HE. Rifaximin if ≥ 2 episodes.

Grade 1 — Mild HE 1

Mild HE: Subtle confusion, attention deficits, asterixis may be present.

→ Identify precipitants. Lactulose (titrate to 2–3 soft stools/day). Rifaximin 550mg BD if on lactulose and recurrent. Avoid benzodiazepines and opioids. Protein restriction not recommended.

Grade 2 — Moderate HE 2

Moderate HE: Lethargy, personality change, obvious confusion, asterixis.

→ Admit. Identify and treat precipitants (SBP, GI bleed, drugs, constipation). Lactulose ± rifaximin. IV thiamine. Nutrition (1.2–1.5 g/kg/day protein). Hepatology review.

Grade 3 — Severe HE 3

Severe HE: Marked confusion, somnolent but rousable.

→ HDU. Airway protection (aspiration risk). NG lactulose if swallowing impaired. IV thiamine, IV glucose, IV fluids. Treat precipitants aggressively. Hepatology consult for transplant assessment.

Grade 4 — Coma 4

Coma: Not rousable. High mortality.

→ ICU. Intubation for airway protection. CT head to exclude intracerebral bleed. Lactulose via NG. Treat precipitants. Urgent liver transplant assessment if appropriate. Mannitol if cerebral oedema in ALF.

Interpretation bands for the Hepatic Encephalopathy Grade. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.